Imbruvica

Lymphoma, Disease, Chronic Lymphocytic Leukemia + 5 more
Treatment
20 Active Studies for Imbruvica

What is Imbruvica

IbrutinibThe Generic name of this drug
Treatment SummaryIbrutinib is a drug used to treat certain types of blood cancer, such as chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's Macroglobulinemia. It works by blocking Burton's tyrosine kinase, an enzyme that helps cancer cells grow. It was approved in 2013 by the FDA and 2014 by the EMA, and more recently in 2017 for use in chronic graft versus host disease.
Imbruvicais the brand name
image of different drug pills on a surface
Imbruvica Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Imbruvica
Ibrutinib
2013
7

Effectiveness

How Imbruvica Affects PatientsLab studies have found that this drug leads to cell death in CLL and inhibits CLL cell survival, migration, and the production of certain chemicals. In clinical trials for CLL, 71% of patients had an overall response rate. For mantle cell lymphoma, 70% of patients had a partial or complete response. For diffuse large B-cell lymphoma, 15-20% of patients had a partial response. For Waldenstrom's macroglobulinemia, over 75% of patients had a partial response. For follicular lymphoma, 54% of patients had a partial to complete response.
How Imbruvica works in the bodyIbrutinib stops Bruton's tyrosine kinase (BTK) from working correctly. It does this by forming a chemical bond with a part of BTK called Cys481. When BTK is blocked, it stops certain signals from reaching downstream molecules like PLC-γ, which helps to prevent the B-cell receptor from working properly.

When to interrupt dosage

The prescribed measure of Imbruvica is subject to the established affliction, including Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma. The quantum of dosage is contingent upon the procedure of deployment as listed in the table underneath.
Condition
Dosage
Administration
Lymphoma
, 140.0 mg, 70.0 mg, 280.0 mg, 420.0 mg, 560.0 mg, 70.0 mg/mL
Oral, , Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Suspension - Oral, Suspension
Disease
, 140.0 mg, 70.0 mg, 280.0 mg, 420.0 mg, 560.0 mg, 70.0 mg/mL
Oral, , Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Suspension - Oral, Suspension
Chronic Lymphocytic Leukemia
, 140.0 mg, 70.0 mg, 280.0 mg, 420.0 mg, 560.0 mg, 70.0 mg/mL
Oral, , Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Suspension - Oral, Suspension
Mantle Cell Lymphoma
, 140.0 mg, 70.0 mg, 280.0 mg, 420.0 mg, 560.0 mg, 70.0 mg/mL
Oral, , Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Suspension - Oral, Suspension
Waldenstrom Macroglobulinemia
, 140.0 mg, 70.0 mg, 280.0 mg, 420.0 mg, 560.0 mg, 70.0 mg/mL
Oral, , Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Suspension - Oral, Suspension
previously treated
, 140.0 mg, 70.0 mg, 280.0 mg, 420.0 mg, 560.0 mg, 70.0 mg/mL
Oral, , Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Suspension - Oral, Suspension
Disease
, 140.0 mg, 70.0 mg, 280.0 mg, 420.0 mg, 560.0 mg, 70.0 mg/mL
Oral, , Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Suspension - Oral, Suspension
rituximab
, 140.0 mg, 70.0 mg, 280.0 mg, 420.0 mg, 560.0 mg, 70.0 mg/mL
Oral, , Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Suspension - Oral, Suspension

Warnings

There are 20 known major drug interactions with Imbruvica.
Common Imbruvica Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Ibrutinib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Acteoside
Major
The risk or severity of adverse effects can be increased when Ibrutinib is combined with Acteoside.
Amitriptyline
Major
The metabolism of Amitriptyline can be decreased when combined with Ibrutinib.
Amoxapine
Major
The metabolism of Amoxapine can be decreased when combined with Ibrutinib.
Antilymphocyte immunoglobulin (horse)
Major
The risk or severity of adverse effects can be increased when Ibrutinib is combined with Antilymphocyte immunoglobulin (horse).
Imbruvica Toxicity & Overdose RiskNo tests have been done to determine if ibrutinib has mutagenic or clastogenic properties, or if it can affect fertility or cause cancer.
image of a doctor in a lab doing drug, clinical research

Imbruvica Novel Uses: Which Conditions Have a Clinical Trial Featuring Imbruvica?

267 active trials are currently assessing the potential of Imbruvica to ameliorate Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.
Condition
Clinical Trials
Trial Phases
Waldenstrom Macroglobulinemia
7 Actively Recruiting
Phase 2, Phase 1
previously treated
0 Actively Recruiting
Mantle Cell Lymphoma
124 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1
rituximab
0 Actively Recruiting
Disease
0 Actively Recruiting
Disease
9 Actively Recruiting
Phase 1, Phase 2, Not Applicable
Chronic Lymphocytic Leukemia
3 Actively Recruiting
Phase 1
Lymphoma
40 Actively Recruiting
Phase 2, Phase 1, Phase 3, Early Phase 1, Not Applicable

Imbruvica Reviews: What are patients saying about Imbruvica?

5Patient Review
3/13/2017
Imbruvica for Chronic Lymphocytic Leukemia
After being diagnosed with CLL in 2010, I finally started using Imbruvica in 2014. My bloodwork is now normal after previously having a WBC of 200K+. Lymph nodes are also back to normal. The only side effects I've experienced are easy bruising, chest congestion, and swollen feet; all of which are manageable.
5Patient Review
3/25/2017
Imbruvica for Chronic Lymphocytic Leukemia with 17p Deletion
I'm on my third month of treatment and so far it's going great. My insurance covers the costs, and I've seen a significant increase in my hemoglobin and platelet levels. My white blood count is also holding steady in the 5.0 range. I haven't experienced any side effects, which is amazing considering I was diagnosed with CLL 10 years ago. I've been treated with Rituxan, Bendamustine and gamma globulin over the past nine years, but when my condition worsened, I switched to Imbruvica. So far it's working wonders and I'm keeping everything crossed
5Patient Review
11/5/2017
Imbruvica for Chronic Lymphocytic Leukemia with 17p Deletion
Ibritinib has been a life-saving medication for me. It's expensive, but it's worth every penny.
5Patient Review
8/8/2017
Imbruvica for Chronic Lymphocytic Leukemia
I've been on this medication for six months and I have seen a significant improvement in my white blood cell count. My lymph nodes are also back to normal size.
5Patient Review
8/15/2017
Imbruvica for Chronic Lymphocytic Leukemia
This medication has been absolutely life-changing. In just six months, my white blood count dropped from 188 to 15. I have some minor side effects, but nothing that's unmanageable.
View All Reviews
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about imbruvica

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Imbruvica a chemotherapy?

"Ibrutinib is a targeted therapy, not a chemotherapy drug. Targeted therapy is the result of years of research dedicated to understanding the differences between cancer cells and normal cells."

Answered by AI

Does Imbruvica cure cancer?

"Imbruvica is used to treat leukemia and lymphoma. Leukemia is a blood cancer and lymphoma is a cancer of the lymph nodes. Lymphocytes are a type of white blood cell."

Answered by AI

What is Imbruvica prescribed for?

"This medication is used to treat cancers such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia. Ibrutinib belongs to a class of drugs known as kinase inhibitors, which work by slowing or stopping the growth of cancer cells."

Answered by AI

How long can you live Imbruvica?

"Patients who stopped taking ibrutinib (Imbruvica) due to intolerance or toxicity had a median survival of 33 months, while those who stopped due to progressive disease or other reasons had a median survival of 16 and 11 months respectively. Patients who developed RT had a median survival of just 2.3 months."

Answered by AI

What are the long term effects of taking Imbruvica?

"It's possible to develop cancers as a side effect of Imbruvica, such as skin cancer, which may require long-term treatment. You may also have heart problems, such as abnormal heart rhythm, after taking Imbruvica."

Answered by AI

Clinical Trials for Imbruvica

Have you considered Imbruvica clinical trials? We made a collection of clinical trials featuring Imbruvica, we think they might fit your search criteria.
Have you considered Imbruvica clinical trials? We made a collection of clinical trials featuring Imbruvica, we think they might fit your search criteria.
Have you considered Imbruvica clinical trials? We made a collection of clinical trials featuring Imbruvica, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top